Are you prepared for the XIENCE short DAPT program? Stay tuned...coming soon TCT Conference Dr Roxana Mehran Dr. Deepak L. Bhatt

1/ COMBINE (OCT–FFR): Using OCT in DM to detect risk FFR negative lesions, according to contemporary trial data, are very low risk for subsequent events. BUT...DM patients are a unique entity. What if we could use OCT, with its incredible resolution, to identify high risk - TCFA.

We’d like to take a moment acknowledge Drs. Domenico D'Amario, Valentina Frittitta, and Antonio Greco for their commitment to personalized vascular care. Thank you for sharing your innovative projects aimed at improving #cardiovascular care for patients at #EuroPCR: bit.ly/3yFtT0D

5-year follow up of DEFINE-FLAIR (iFR vs FFR-guided revascularisation) presented by Javier Escaned #EuroPCR2023 ➡️ MACE higher in iFR arm (HR 1.18; CI 0.99 - 1.41, p=0.07) ➡️ All-cause death 3% higher in iFR arm (HR 1.51; CI 1.22 - 2.90) ➡️ Difference driven by CV death

“Hot Line 4 is very important and will probably be the highlight of the Hot Lines for many cardiovascular health professionals. It includes a series of trials – ILUMIEN IV, OCTIVUS and OCTOBER..." Lene Nyhus Andreasen Evald Høj Christiansen Omeed Neghabat jcspratt #cardotwitter #octfirst

#ESC2024 European Society of Cardiology FAME 2: 10-year follow-up 🏪 PCI is 25% more likely to lead to better outcomes than medical therapy alone 🔑 48% of patients were tied. Nearly half the time, it won't make a big difference which one you choose. PCRonline 🫀 CoreAalst Hartcentrum Aalst Optima Education